Skip to main content

Advertisement

SpringerLink
Log in

Terapia radiorecettoriale dei tumori neuroendocrini pancreatici

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

An Erratum to this article was published on 01 June 2016

Sommario

La terapia radiorecettoriale con 177Lu-DOTATATE (Lu-PRRT) è una valida opzione di terapia mirata nei tumori neuroendocrini pancreatici G1–G2 (pNET). È una terapia efficace in oltre l’80% dei casi. Complessivamente è ben tollerata, con tossicità midollare e renale lieve e reversibile, in particolare con frazionamento della dose totale di radiofarmaco. Nella gestione dei pazienti pNET, la PET con FDG è un importante fattore prognostico legato al metabolismo glucidico tumorale.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Bibliografia

  1. Lawrence B, Gustafsson BI, Chan A et al. (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40:1–18

    Article  Google Scholar 

  2. Klimstra DS, Modlin IR, Coppola D et al. (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39(6):707

    Article  PubMed  Google Scholar 

  3. Rindi G, Arnold R, Bosman FT et al. (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system. IARC Press, Lyon, pp 13–14

    Google Scholar 

  4. Akerström G, Falconi M, Kianmanesh R et al. (the Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society) (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology 90(2):203–208

    Article  PubMed  Google Scholar 

  5. Bodei L, Cremonesi M, Grana C et al. (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31(7):1038–1046

    Article  CAS  PubMed  Google Scholar 

  6. Bodei L, Cremonesi M, Ferrari M et al. (2008) Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with (90)Y-DOTATOC and (177)Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35(10):1928

    Article  Google Scholar 

  7. Ngo DC, Ververis K, Tortorella SM et al. (2015) Introduction to the molecular basis of cancer metabolism and the Warburg effect. Mol Biol Rep 42(4):819–823

    Article  CAS  PubMed  Google Scholar 

  8. Binderup T, Knigge U, Loft A et al. (2010) 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 16(3):978–985

    Article  CAS  PubMed  Google Scholar 

  9. Severi S, Nanni O, Bodei L et al. (2013) Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40(6):881–888

    Article  CAS  PubMed  Google Scholar 

  10. Kwekkeboom DJ, de Herder WW, Kam BL et al. (2008) Treatment with radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]ocreotate: toxicity, efficacy and survival. J Clin Oncol 26(13):2124–2130

    Article  CAS  PubMed  Google Scholar 

  11. Yao JC, Shah MH, Ito T et al. (the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group) (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Paganelli G, Sansovini M, Ambrosetti A et al. (2014) 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging 41(10):1845–1851

    Article  CAS  PubMed  Google Scholar 

  13. Rindi G, Wiedemann B (2012) Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 8:54–64

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. U.C. di Medicina Nucleare e Terapia Radiometabolica, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST-IRCCS), Via P. Maroncelli 40, 47014, Meldola, FC, Italia

    Silvia Nicolini, Maddalena Sansovini, Stefano Severi, Annarita Ianniello, Federica Matteucci & Giovanni Paganelli

  2. Unità di Biostatistica e Sperimentazioni Cliniche, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST-IRCCS), Meldola, Italia

    Manuela Monti

Authors
  1. Silvia Nicolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maddalena Sansovini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefano Severi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manuela Monti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Annarita Ianniello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Federica Matteucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giovanni Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Paganelli.

Ethics declarations

Conflitto di interesse

Gli autori Silvia Nicolini, Maddalena Sansovini, Stefano Severi, Manuela Monti, Annarita Ianniello, Federica Matteucci e Giovanni Paganelli dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da Francesco Trimarchi.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 31 kB)

(DOC 29 kB)

(DOC 41 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nicolini, S., Sansovini, M., Severi, S. et al. Terapia radiorecettoriale dei tumori neuroendocrini pancreatici. L'Endocrinologo 17, 21–27 (2016). https://doi.org/10.1007/s40619-016-0170-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-016-0170-5

Parole chiave

Search

Navigation